Acadia pharmaceuticals reports second quarter 2025 financial results and operating overview

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced its financial results for the second quarter ended june 30, 2025. “acadia continued to build momentum in the second quarter, resulting in total revenue of $264.6 million,” said catherine owen adams, chief executive officer. “nuplazid delivered a very strong quarter, particularly in terms of referrals and new patient starts, driven by strong commercial execution and increased engagement from our direct-to-cons.
ACAD Ratings Summary
ACAD Quant Ranking